Capricor Therapeutics Inc Stock OTC Bulletin Board
Stocks
CAPR
US14070B1017
Biotechnology & Medical Research
| Market Cap | 366M 313M 293M 268M 503M 35B 510M 3.46B 1.35B 17.56B 1.37B 1.34B 58.12B | P/E 2026 * |
-2.83x | P/E 2027 * | -3.8x |
|---|---|---|---|---|---|
| Enterprise Value | 366M 313M 293M 268M 503M 35B 510M 3.46B 1.35B 17.56B 1.37B 1.34B 58.12B | EV / Sales 2026 * |
23.1x | EV / Sales 2027 * | 8.46x |
| Free-Float |
90.56% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Capricor Therapeutics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 62 | 2013-11-19 |
Anthony Bergmann
DFI | Director of Finance/CFO | 40 | 2017-12-31 |
Michael Binks
CTO | Chief Tech/Sci/R&D Officer | - | 2025-05-12 |
| Director | Title | Age | Since |
|---|---|---|---|
Frank Litvack
CHM | Chairman | 70 | 2013-10-31 |
David Musket
BRD | Director/Board Member | 68 | 2013-11-19 |
George Dunbar
BRD | Director/Board Member | 79 | 2013-11-19 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 366M | |
| -3.00% | +2.27% | +77.60% | +109.33% | 72.12B | |
| +1.90% | +23.53% | +59.48% | +94.82% | 65.85B | |
| +5.12% | +25.22% | +5.13% | -5.86% | 29.28B | |
| +0.55% | +1.64% | -4.63% | +480.92% | 27.47B | |
| +2.74% | +12.98% | +62.84% | +28.14% | 26.7B | |
| +0.47% | +6.12% | +36.66% | -13.79% | 20.06B | |
| +1.82% | -6.67% | +247.46% | +393.10% | 18.22B | |
| +0.94% | +3.36% | +18.55% | +532.94% | 16.4B | |
| +0.73% | +5.54% | +39.99% | +151.77% | 13.4B | |
| Average | +1.13% | +8.36% | +60.34% | +196.82% | 32.17B | |
| Weighted average by Cap. | +0.74% | +9.48% | +59.75% | +157.44% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 15.82M 13.55M 12.67M 11.6M 21.78M 1.51B 22.07M 150M 58.35M 760M 59.4M 58.11M 2.51B | 43.24M 37.02M 34.63M 31.7M 59.51M 4.14B 60.31M 409M 159M 2.08B 162M 159M 6.87B |
| Net income | -129M -111M -103M -94.65M -178M -12.36B -180M -1.22B -476M -6.2B -485M -474M -20.52B | -99.36M -85.09M -79.57M -72.85M -137M -9.51B -139M -940M -366M -4.77B -373M -365M -15.79B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
